Company: Amphista Therapeutics
Job title: Chief Scientific Officer
Ian was one of the pioneers of the recent renaissance of the PROTAC field through his 2012 collaboration with Prof Craig Crews & Alessio Ciulli when leading the GSK PROTAC group (2012-2017) including the publication of the landmark 2015 Nature Chemical Biology paper and advancing a portfolio of VHL & IAP-based PROTACs towards the clinic. Ian also has extensive experience of medicinal chemistry & chemical biology leadership from roles at Merck & GSK across many therapy areas including neuroscience, oncology, inflammation and others. More recently, Ian led the R&D team at BenevolentAI where he applied novel artificial intelligence methods to a portfolio of projects to approach target identification and chemical optimisation in new ways. Ian returned to the TPD field in May 2020 as CSO at Amphista Therapeutics, the leading European-based targeted protein degradation company focused exclusively on using novel degrading mechanisms to advance a range of programmes towards the clinic.
New Approaches to Degradation – Beyond the Usual Suspects 9:30 am
First public disclosure of the Amphista platform using a completely novel range of mechanisms to degrade a wide range of disease-relevant proteins Mechanisms go beyond the usual E3 ligases utilized by most in the field and instead use other UPS proteins which offer new opportunities to expand the scope and utility of TPD strategies We…Read more
day: Day Two